Comparative Pharmacology
Head-to-head clinical analysis: LIPOFEN versus TRICOR MICRONIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOFEN versus TRICOR MICRONIZED.
LIPOFEN vs TRICOR (MICRONIZED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipofen (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It activates PPARα, which increases lipolysis and elimination of triglyceride-rich particles from plasma by stimulating lipoprotein lipase activity and reducing apolipoprotein C-III production. This leads to decreased triglyceride levels and increased HDL cholesterol.
Tricor (micronized fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
For hypertriglyceridemia: 67-134 mg (as fenofibric acid) orally three times daily with meals. Maximum dose 200 mg/day.
Initial 48 mg (1 tablet) orally once daily with meals. May increase to 96 mg (2 tablets) once daily with meals. Maximum dose 96 mg/day.
None Documented
None Documented
5-7 hours (prolonged in renal impairment; may exceed 24 hours in severe CKD).
Terminal elimination half-life is approximately 20 hours (range 15-25 hours) in patients with normal renal function. Half-life is prolonged in renal impairment, requiring dose adjustment when eGFR < 30 mL/min/1.73 m².
Primarily renal (90% as unchanged drug), with <5% fecal.
Primarily renal excretion of glucuronide conjugate, accounting for approximately 60-70% of elimination; fecal excretion accounts for about 25%. Minimal unchanged drug in urine.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic